CMS specialty measure sets may be reported as an alternative to reporting 6 separate quality measures. If a measure set has less than 6 measures, eligible groups and clinicians must report all measures in the set. However, if a set has more than 6 measures, participants may choose the 6 measures that best fit their practice. Remember, at least one outcome measure must be reported, regardless of whether or not an outcome measure is included in a measure set.
|Quality Id||Measure Name||High Priority||Measure Type||Measure Description|
|107||2022 MIPS Measure #107: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment||eCQM||All patient visits during which a new diagnosis of MDD or a new diagnosis of recurrent MDD was identified for patients aged 18 years and older with a suicide risk assessment completed during the visit||View|
|382||2022 MIPS Measure #382: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment||eCQM||Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk||View|
|281||2022 MIPS Measure #281: Dementia: Cognitive Assessment||eCQM||Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period||View|
|366||2022 MIPS Measure #366: Follow-Up Care for Children Prescribed ADHD Medication (ADD)||eCQM||Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.||View|
|128||2022 Measure # 128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan||no||Process||Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous twelve months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous twelve months of the current encounter||View|
|130||2022 Measure # 130 Documentation of Current Medications in the Medical Record||yes||Process||Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications’ name, dosage, frequency and route of administration||View|
|134||2022 Measure # 134 Preventive Care and Screening: Screening for Depression and Follow-Up Plan||no||Process||Percentage of patients aged 12 years and older screened for depression on the date of the encounter or 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter||View|
|181||2022 Measure # 181 Elder Maltreatment Screen and Follow-Up Plan||yes||Process||Percentage of patients aged 65 years and older with a documented elder maltreatment screen using an Elder Maltreatment Screening tool on the date of encounter AND a documented follow-up plan on the date of the positive screen||View|
|226||2022 Measure # 226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention||no||Process||Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within the measurement period AND who received tobacco cessation intervention on the date of the encounter or within the previous 12 months if identified as a tobacco user||View|
|282||2022 Measure # 282 Dementia: Functional Status Assessment||no||Process||Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months.||View|
|283||2022 Measure # 283 Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management||no||Process||Percentage of patients with dementia for whom there was a documented screening for behavioral and psychiatric symptoms, including depression, and for whom, if symptoms screening was positive, there was also documentation of recommendations for management in the last 12 months||View|
|286||2022 Measure # 286 Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia||yes||Process||Percentage of patients with dementia or their caregiver(s) for whom there was a documented safety concerns screening in two domains of risk: 1) dangerousness to self or others and 2) environmental risks; and if safety concerns screening was positive in the last 12 months, there was documentation of mitigation recommendations, including but not limited to referral to other resources||View|
|288||2022 Measure # 288 Dementia: Education and Support of Caregivers for Patients with Dementia||yes||Process||Percentage of patients with dementia whose caregiver(s) were provided with education on dementia disease management and health behavior changes AND were referred to additional resources for support in the last 12 months||View|
|370||2022 Measure # 370 Depression Remission at Twelve Months||yes||Outcome||The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event date.||View|
|374||2022 Measure # 374 Closing the Referral Loop: Receipt of Specialist Report||yes||Process||Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred||View|
|383||2022 Measure # 383 Adherence to Antipsychotic Medications for Individuals with Schizophrenia||yes||Intermediate Outcome||Percentage of individuals at least 18 years of age as of the beginning of the performance period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the performance period||View|
|391||2022 Measure # 391 Follow-up After Hospitalization for Mental Illness (FUH)||yes||Process||The percentage of discharges for patients 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider.||View|
|402||2022 Measure # 402 Tobacco Use and Help with Quitting Among Adolescents||no||Process||The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user||View|
|431||2022 Measure # 431 Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling||no||Process||Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 12 months AND who received brief counseling if identified as an unhealthy alcohol user||View|
|468||2022 Measure # 468 Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)||yes||Process||Percentage of adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment||View|
Stay up to date with the latest news regarding MACRA and MIPS.
The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.